Takeda Pharmaceutical Co (SSE:4502) Debt-to-Equity : 0.69 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Takeda Pharmaceutical Co Debt-to-Equity?

Takeda Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円370,292 Mil. Takeda Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円4,293,872 Mil. Takeda Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円6,741,934 Mil. Takeda Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Takeda Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SSE:4502' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34 Med: 0.67 Max: 1.25
Current: 0.69

During the past 13 years, the highest Debt-to-Equity Ratio of Takeda Pharmaceutical Co was 1.25. The lowest was 0.34. And the median was 0.67.

SSE:4502's Debt-to-Equity is ranked worse than
77.92% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs SSE:4502: 0.69

Takeda Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Takeda Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Debt-to-Equity Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

1.11

1.08

0.90

0.77

0.69

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.69	0.69	0.69	0.66	0.69

Competitive Comparison of Takeda Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Debt-to-Equity falls into.

Takeda Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Takeda Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(339600	+	4042741)	/	6354122
	=	0.69

Takeda Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(370292	+	4293872)	/	6741934
	=	0.69

Takeda Pharmaceutical Co (SSE:4502) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Takeda Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (SSE:4502) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (SSE:4502) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TAK:USA TKPHF:USA TAK:Mexico 4502:Japan TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (SSE:4502) Headlines

No Headlines